Skip to content

Oral Midazolam for Sedation in Esophagogastroduodenoscopy(EGD)

Effectiveness of Oral Midazolam for Sedation in Patients Undergoing Upper Gastrointestinal Endoscopy

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01990937
Enrollment
260
Registered
2013-11-25
Start date
2013-10-31
Completion date
2015-02-28
Last updated
2014-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Conscious Sedation Failure During Procedure

Keywords

oral midazolam, sedation, premedication, upper gastrointestinal endoscopy, EGD

Brief summary

Can oral midazolam used for sedation in patients undergoing upper gastrointestinal endoscopy ?

Detailed description

Five mg of midazolam was intake orally about 30 minutes before undergoing perform upper gastrointestinal endoscopy. Declined of anxiety scores was primary end point.

Interventions

5 mg in 15 mL of apple juice, orally 30 minutes before undergoing EGD

Sponsors

Phramongkutklao College of Medicine and Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Scheduled to undergo elective diagnostic EGD * American Society of Anesthesia (ASA) criteria to be class 1 to 2

Exclusion criteria

* History of gastrectomy, esophagectomy, pancreaticoduodenectomy, or other operation on the upper-GI tract * American Society of Anesthesia (ASA) criteria to be class 3 to 4 * Pregnancy * Alcoholism * Drug abuse * Taking psychotic medications * Allergy to midazolam.

Design outcomes

Primary

MeasureTime frameDescription
Difference of Anxiety scoreAsked the patient 5 minutes before EGD and then after fully recovery from sedation.* Anxiety score is 10-cm scaled visual analog scale. * Anxiety score which asked the patient 5 minutes before EGD, called Pre EGD anxiety score * Anxiety score which asked the patient after fully recovery, called During EGD anxiety score. * Difference of anxiety score means Pre EGD minus During anxiety score. * Fully recovery means fully gain of consiouness (time, place, person).

Secondary

MeasureTime frameDescription
Overall toleranceAsked the patient after fully recovery from sedation.Fully recovery means fully gain of consiouness (time, place, person). Overall tolerance was grading into 4 levels; * Poor : Very uncomfortable during the entire procedure * Fair : Uncomfortable during most of the procedure * Good : Believes the procedure was generally comfortable, there were portions of procedure during which sedation could have been given * Excellent : Believes the procedure was comfortable, no additional sedation was needed

Other

MeasureTime frameDescription
Overall satisfactionAsked the patient after fully recovery from sedation.Fully recovery means fully gain of consiouness (time, place, person). Overall satifaction was 10-cm scaled visual analog scale.
Amnesia scoreAsked the patient after fully recovery from sedation.Fully recovery means fully gain of consiouness (time, place, person). Amnesia score was grading into 4 levels; 1. = Patient unable to recall any portion of procedure 2. = Able to recall and describe some portion of procedure 3. = Able to recall and describe most of procedure 4. = Able to recall and describe entire procedure
Willing to repeat EGDAsked the patient after fully recovery from sedation.Fully recovery means fully gain of consiouness (time, place, person). Willing to repeat EGD was defined to Yes or No.
Vital signsVital signs were measured at 5 minutes before EGD then measured every 5 minutes during EGD until the patient was fully recovery after the EGD was finished.Vital signs were blood pressure(mmHg), heart rates(beats per minute), respiratory rates(per minute) and oxygen saturation(percents).

Countries

Thailand

Contacts

Primary ContactChaipichit Puttapitakpong, Doctor
iamkeang@hotmail.com6681707-3005

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026